Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Receivables (2016 - 2025)

Bio-Techne (TECH) has 16 years of Receivables data on record, last reported at $184.6 million in Q4 2025.

  • For Q4 2025, Receivables fell 15.29% year-over-year to $184.6 million; the TTM value through Dec 2025 reached $184.6 million, down 15.29%, while the annual FY2025 figure was $206.9 million, 14.3% down from the prior year.
  • Receivables reached $184.6 million in Q4 2025 per TECH's latest filing, roughly flat from $183.9 million in the prior quarter.
  • Across five years, Receivables topped out at $241.4 million in Q2 2024 and bottomed at $145.4 million in Q2 2021.
  • Average Receivables over 5 years is $196.5 million, with a median of $203.3 million recorded in 2022.
  • Peak YoY movement for Receivables: soared 34.34% in 2021, then dropped 17.79% in 2025.
  • A 5-year view of Receivables shows it stood at $152.9 million in 2021, then grew by 20.84% to $184.8 million in 2022, then grew by 12.28% to $207.5 million in 2023, then rose by 5.06% to $217.9 million in 2024, then dropped by 15.29% to $184.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $184.6 million in Q4 2025, $183.9 million in Q3 2025, and $206.9 million in Q2 2025.